9 Hidden Life Sciences Operational Cost Drains And How to Fix Them

California’s life sciences ecosystem moves fast. Companies are advancing science, chasing milestones, managing regulatory timelines, and competing for capital. In that environment, operational spending doesn’t always get the scrutiny it deserves. When that happens, cost drains are the result.

It’s not a failure of judgment. It’s a reality of working at speed and under pressure. But small inefficiencies compound quietly, and over time, they create friction, slow teams down, and can eat up runway.

At California Life Sciences, we work with companies at every stage—from pre-seed startups to established biopharma leaders. Across that spectrum, we see the same patterns emerge. Below are nine of the most common places life sciences companies lose money without realizing it, and what you can do about each one.

1. Paying retail for specialized tools and services

When procurement decisions are made closest to the work—by the researcher who needs something now, or the lab manager working to a deadline—paying list price is faster and in the moment, it can feel like the only option.

The problem is when retail price can become the baseline. Convenience trumps price, one purchase leads to another, and in time, recurring line items are absorbing 15–30% more than they need to. Research from Genetic Engineering & Biotechnology News found that pricing on some plastic lab consumables can vary as much as 80% depending on the supplier.

It’s not just consumables; with services, subscriptions, software, and supplies, it pays to shop around and negotiate.

What to watch for:

Standard supplier pricing on high-frequency purchases (reagents, consumables, software subscriptions)
No formal vendor negotiation process at any stage of company growth
Procurement made at the individual level with no visibility across the team

What CLS members do differently

Through the CLS Cost Savings Program (formerly CLS Advantage), members access pre-negotiated pricing across vetted partners—giving even early-stage companies the purchasing leverage of much larger organizations. According to CLS membership data, annual average savings scale significantly with company size:

Members with 1–20 employees save $20,783 per year on average
Members with 21–100 employees save $129,243 per year on average
Companies with 100+ employees save $587,566 per year on average

2. Underestimating the true cost of switching vendors

Switching vendors can look like an obvious cost-saving move on paper; if you find a 15% lower unit price, the math seems simple. But what the spreadsheet doesn’t typically capture are the indirect costs of such a change.

Retraining staff, revalidating processes, renegotiating terms, and managing a period of reduced productivity often add up to more than the initial savings. In regulated environments, revalidation alone can represent weeks of team time.

What to watch for:

Vendor decisions driven exclusively by quoted price
No formal evaluation of transition costs before switching
Underestimating the time burden on scientific staff during changeovers

The right question to ask:

Before switching vendors, calculate the full cost, considering factors such as:

Revalidation time
Staff hours
Productivity loss
Risk of supply disruption

Many times, optimizing terms with your existing vendor—something CLS’s vetted network can help facilitate—delivers better outcomes than a switch.

3. Building infrastructure for the company you aren’t yet

Early-stage companies can invest in systems, facilities, or organizational structures designed for a stage of growth that’s still years away. The reasoning is understandable: it’s better to build it right the first time.

But ‘right’ has a time component. Infrastructure built too early means paying for complexity, capacity, and maintenance you won’t fully use for years to come. According to McKinsey’s biotech operations research, G&A expenses for pre-clinical companies can range from $19M to $30M annually, with wide variance that often reflects over-engineering relative to actual stage.

What to watch for:

Lab space or software platforms sized for a much larger organization
Complex ERP or LIMS implementations before operational need dictates
Redundant infrastructure built to hedge against supply risk that hasn’t materialized

A more scalable approach:

Scale infrastructure to your current critical path, not your aspirational org chart. CLS members gain access to ecosystem resources including shared facilities, trusted CRO networks, and cost benchmarks from peer companies. All intended to calibrate infrastructure investment to the actual company stage.

4. Fragmented purchasing across teams and locations

As companies grow, procurement can follow the org chart as opposed to a centralized strategy. Different departments, sites, or research teams purchase independently, each negotiating (or not) their own terms. The result is widely varying pricing for the same items, inconsistent service levels, and no visibility into aggregate spend.

Volume-based discounts require volume. Fragmented purchasing makes it structurally impossible to leverage the buying power a company actually has.

What to watch for:

No centralized purchasing or spend management function
Multiple contracts with the same supplier at different negotiated rates
No cross-departmental visibility into vendor relationships or aggregate spend

The consolidation opportunity:

Centralizing even informal spend visibility before investing in a formal procurement platform creates immediate opportunities to consolidate vendors and unlock volume pricing. CLS cost savings partners are structured around aggregated purchasing across the California life sciences ecosystem, extending scale benefits to member companies regardless of size.

5. Letting small inefficiencies run indefinitely

A workflow that takes 20 minutes longer than it should. A service issue that gets resolved each time but never corrected. An approval process that requires three people when one would do. Individually, these issues are small but together, they can create a big problem that slows progress and costs money.

Small inefficiencies rarely trigger an action threshold. If there’s no single moment where the cost becomes obvious enough to force a fix, the problem will go unfixed.

What to watch for:

Recurring frustrations that teams have learned to work around
Workflows that made sense at five employees but haven’t scaled to serve 50
Vendor service issues that generate tickets repeatedly without ever fixing the root cause

Worth remembering:

For early-stage companies with average burn rates around $20,000 per employee per month, even modest efficiency gains compound meaningfully over a 24-month runway. Time spent on friction is time not spent on progress.

6. Choosing vendors without life sciences expertise

A generalist vendor is often cheaper upfront and faster to onboard. But in a regulated industry, lack of domain knowledge creates downstream problems that can cost more than the initial savings.

Compliance gaps, misaligned expectations about turnaround timelines, rework caused by unfamiliarity with GxP requirements, and the organizational friction of having to educate vendors on industry basics come with real costs that rarely appear in a vendor evaluation.

What to watch for:

Vendors without clear understanding of the regulatory environment
Service agreements that don’t reflect life sciences compliance requirements
Rework or delays traceable to vendor unfamiliarity with the operating environment

The vetting advantage:

The CLS partner network comprises life sciences experts. Partners understand the regulatory context, know the operational cadence of the industry, and have track records with companies across the ecosystem. That’s a different risk profile than going to market independently.

7. Treating service quality as secondary purchasing criterion

When budgets are tight, companies may look to cut costs by compromising on support and service levels. In this situation, the lowest-cost option wins, and important criteria like response time or expertise aren’t weighed heavily in the decision.

The cost of that choice can show up as downtime. A stalled experiment, delayed support response, or equipment issue that takes days to resolve can directly impact timelines and team morale and can more than offset any initial savings.

What to watch for:

Vendor selection processes that don’t evaluate service response benchmarks
Little understanding of what downtime actually costs on a per-day basis
Selecting support packages on price without properly assessing need

A useful reframe:

Service quality isn’t overhead, it’s insurance against timeline risk. The right vendor with excellent support can protect against delays that cost far more than the premium.

8. Failing to revisit contracts as the company grows

Contracts signed during early fundraising, or negotiated for a company at a very different stage, can persist long past their useful life. Contracts negotiated in an earlier stage in the company’s growth worked then but as headcount or usage increases, they may no longer reflect the company’s leverage or needs.

The reverse is also true: enterprise contracts signed without meaningful usage projections can lock smaller teams into paying for services that’ll never come back as value.

What to watch for:

Multi-year contracts that haven’t been reviewed since signing
Vendor agreements that predate significant company growth milestones
Benefits or services included in contracts that teams aren’t actively using

Build in a review cycle:

Tying contract reviews to annual planning cycles or funding milestones ensures terms stay aligned with the company’s actual stage. Growth should unlock better terms, not higher costs by default.

9. Not tapping the resources the ecosystem already offers

California has a vibrant life sciences ecosystem. You might even say limitless possibilities live here. This ecosystem has generated decades of shared infrastructure, vetted partnerships, peer knowledge, and collective purchasing leverage. Companies, particularly those new to California or in early growth stages, may not know of all that’s available to them.

Operating in isolation when ecosystem resources exist is a cost that’s easy to avoid but only if you know where to look.

What to watch for:

No connection to the state or regional life sciences association network
Vendor relationships built through individual outreach rather than vetted referrals
No access to industry benchmarking data for cost or operational norms

What membership makes available:

Through California Life Sciences membership, companies access negotiated pricing with vetted partners, peer benchmarks, shared best practices, and the collective purchasing power of the broader California ecosystem, without having to build that expertise and infrastructure independently.

Cutting friction, not corners

Most cost leakage in life sciences companies is not dramatic. It’s structural, incremental, and can become invisible day to day.

The goal is not to slow innovation or cut corners. It’s to remove unnecessary friction so teams can focus on the work that matters most.

The pressure is real and growing: nearly 60% of life sciences executives surveyed by Deloitte identified optimizing their operating model as a priority for 2025. Programs like the CLS Cost Savings Program exist to help companies act on that priority—giving teams of every size access to vetted partners, negotiated pricing, and ecosystem intelligence that would take years to build independently. Smarter operational decisions don’t require more effort. They require better visibility.